Skip to main content

Advertisement

Table 3 Grade 3 to 4 adverse events of interest

From: Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review

AEs I 2 OR 95 % CI P value
Anemia 0.0 % 1.02 0.83–1.24 0.883
Thrombocytopenia 39.2 % 1.06 0.74–1.51 0.771
Leucopenia 66.1 % 1.24 0.73–2.10 0.433
Neutropenia 85.8 % 1.33 0.88–2.01 0.179
Febrile neutropenia 67.2 % 1.34 0.68–2.67 0.401
Hypokalemia 38.1 % 1.09 0.81–1.47 0.586
Rash 0.0 % 21.84 6.81–70.02 <0.001*
Hand-foot syndrome 37.6 % 1.75 1.22–2.50 0.002*
Stomatitis 42.8 % 2.08 1.23–3.51 0.006*
Nausea 21.6 % 0.94 0.73–1.21 0.639
Vomit 0.3 % 0.99 0.79–1.25 0.944
Abdominal pain 0.0 % 1.10 0.47–2.57 0.821
Diarrhea 14.1 % 2.40 1.88–3.06 <0.001*
Constipation 0.0 % 0.27 0.08–0.91 0.034*
Decreased appetite 0.0 % 1.13 0.88–1.46 0.342
Fatigue 0.0 % 1.55 1.21–2.00 0.001*
Neuropathy 62.8 % 0.76 0.24–2.41 0.636
Any adverse events 86.8 % 1.53 0.98–2.40 0.062
  1. *P < 0.005, There were statistically significant differences between the two arms